<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03607669</url>
  </required_header>
  <id_info>
    <org_study_id>AC16109</org_study_id>
    <nct_id>NCT03607669</nct_id>
  </id_info>
  <brief_title>Manganese-Enhanced Magnetic Resonance Imaging of the Myocardium</brief_title>
  <official_title>Manganese-Enhanced Magnetic Resonance Imaging: Applications in Cardiomyopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Edinburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Scanning the heart using magnetic resonance imaging (MRI) enables detailed assessment of its&#xD;
      structure and function. MRI can give more detailed information about the heart by using a&#xD;
      contrast 'dye' that is injected into a vein during the scan. This can highlight abnormal&#xD;
      areas within the heart. Current contrast dyes help identify scarring within the heart, which&#xD;
      is useful in people who have had heart attacks. The investigators plan to test new contrast&#xD;
      dye containing manganese, which works differently to current agents. They believe it will&#xD;
      provide unique insight into how the heart works.&#xD;
&#xD;
      There are many different causes of heart problems and the investigators plan to use this new&#xD;
      contrast agent to scan three patient groups; (i) heart disease caused by heart attacks, (ii)&#xD;
      heart disease with abnormal thickening of the heart muscle, and (iii) heart disease where the&#xD;
      heart becomes stretched and enlarged. Healthy volunteers will be scanned for comparison.&#xD;
&#xD;
      The study will be carried out at the Royal Infirmary of Edinburgh. Adults between 18 and 65&#xD;
      with stable heart failure can be considered. Women who may be pregnant are unable to&#xD;
      participate, as is anyone who has some types of metal in their body, as these people can't&#xD;
      have an MRI scan safely. All participants will have 2 MRI scans lasting about an hour each,&#xD;
      at least 2 days apart. Some participants will be have 4 MRI scans, over a longer time period.&#xD;
      The investigators will also take some blood samples and record a tracing of the heart rhythm&#xD;
      and will ensure there are no abnormal side-effects by telephone follow up.&#xD;
&#xD;
      The investigators believe this new agent has potential to better measure disease in the&#xD;
      heart, improve the ability to establish the cause of heart disease and help monitor the&#xD;
      disease over time as well as guide future treatment for individual patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Myocardial calcium-handling</measure>
    <time_frame>1 year</time_frame>
    <description>Quantification of myocardial calcium handling by T1 mapping, in healthy controls, and patient groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction quantification</measure>
    <time_frame>1 year</time_frame>
    <description>Quantification of infarct size using manganese, and comparison with Gadolinium enhanced MRI.</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Ischemic Cardiomyopathy</condition>
  <condition>Dilated Cardiomyopathy</condition>
  <condition>Hypertrophic Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Healthy Controls</arm_group_label>
    <description>Healthy volunteers of similar age and gender</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ischaemic Cardiomyopathy</arm_group_label>
    <description>Patients with ischaemic cardiomyopathy and NYHA II-III heart failure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypertrophic Cardiomyopathy</arm_group_label>
    <description>Patients with hypertrophic cardiomyopathy and NYHA II-III heart failure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dilated Cardiomyopathy</arm_group_label>
    <description>Patients with dilated cardiomyopathy and NYHA II-III heart failure</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Mangafodipir trisodium</intervention_name>
    <description>Manganese-based MRI contrast agent</description>
    <arm_group_label>Dilated Cardiomyopathy</arm_group_label>
    <arm_group_label>Healthy Controls</arm_group_label>
    <arm_group_label>Hypertrophic Cardiomyopathy</arm_group_label>
    <arm_group_label>Ischaemic Cardiomyopathy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients attending the Edinburgh Heart Centre will be invited to participate. Inpatients&#xD;
        and outpatients are eligible. Healthy volunteers will be invited to participate by local&#xD;
        recruitment.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All subjects to be entered must:&#xD;
&#xD;
          -  ≥ 18 years of age&#xD;
&#xD;
          -  if female, be non-pregnant as evidenced by a urine pregnancy test or post-menopausal&#xD;
             or surgically sterile&#xD;
&#xD;
          -  provide written informed consent after having received oral and written information&#xD;
             about the study&#xD;
&#xD;
        Additionally, cohort-specific inclusion criteria as follows:&#xD;
&#xD;
        Healthy Volunteers&#xD;
&#xD;
        • Healthy adult with no known pre-existing medical conditions&#xD;
&#xD;
        Ischaemic Cardiomyopathy&#xD;
&#xD;
          -  Ischaemic cardiomyopathy as diagnosed by reduced LV ejection fraction (≤40%) secondary&#xD;
             to one or more ischaemic events&#xD;
&#xD;
          -  Angiographically demonstrated LMS, LAD disease, or ≥2 vessel disease&#xD;
&#xD;
          -  NHYA class I-III heart failure, with stable symptoms not requiring change to diuretic&#xD;
             therapy in the preceding month&#xD;
&#xD;
        Dilated Cardiomyopathy&#xD;
&#xD;
          -  Dilated cardiomyopathy characterised with echocardiography by reduced left ventricular&#xD;
             systolic function with impaired systolic function (ejection fraction &lt;40%).&#xD;
&#xD;
          -  NHYA class I-III heart failure, with stable symptoms not requiring change to diuretic&#xD;
             therapy in the preceding month&#xD;
&#xD;
        Hypertrophic Cardiomyopathy&#xD;
&#xD;
          -  Established diagnosis of hypertrophic cardiomyopathy&#xD;
&#xD;
          -  Left ventricular wall thickness ≥15mm in any segment&#xD;
&#xD;
          -  Repolarisation abnormalities on 12-lead electrocardiogram NHYA class I-III heart&#xD;
             failure, with stable symptoms not requiring change to diuretic therapy in the&#xD;
             preceding month&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  have a positive pregnancy test&#xD;
&#xD;
          -  women who are breast feeding&#xD;
&#xD;
          -  received an investigational drug or device within 30 days prior to administration of&#xD;
             Mangafodipir&#xD;
&#xD;
          -  have known hypersensitivity to ondansetron or other selective serotonin 5-HT3 receptor&#xD;
             blockers&#xD;
&#xD;
          -  have a history of ongoing drug abuse or alcoholism&#xD;
&#xD;
          -  have a history of torsades or prolonged QT/QTc interval&#xD;
&#xD;
          -  atrioventricular block (1st, 2nd or 3rd degree)&#xD;
&#xD;
          -  atrial fibrillation or flutter&#xD;
&#xD;
          -  have NYHA Grade IV heart failure&#xD;
&#xD;
          -  have abnormal liver function tests or a history of liver disease&#xD;
&#xD;
          -  have a baseline eGFR (estimated glomerular filtration rate) of &lt;30 mL/min)&#xD;
&#xD;
          -  have uncontrolled hypertension&#xD;
&#xD;
          -  have any contraindications to MRI, including implanted devices/pacemakers&#xD;
&#xD;
          -  be maintained on either a calcium channel blocker or digoxin&#xD;
&#xD;
          -  known diagnosis of phaeochromocytoma&#xD;
&#xD;
        Additionally, cohort-specific exclusion criteria as follows:&#xD;
&#xD;
        Hypertrophic Cardiomyopathy&#xD;
&#xD;
          -  Coronary artery stenosis &gt;50% any vessel&#xD;
&#xD;
          -  Previous myocardial infarction&#xD;
&#xD;
          -  Previous alcohol septal ablation&#xD;
&#xD;
          -  Moderate or severe aortic stenosis (mean gradient &gt;25 mmHg, mean AVA ≤1.5 cm2 or peak&#xD;
             velocity ≥3 m/sec),&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David E Newby, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Edinburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicholas B Spath</last_name>
    <phone>0131 242 6515</phone>
    <email>nick.spath@ed.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sponsor Representative</last_name>
    <phone>0131 242 3330</phone>
    <email>enquiries@accord.scot</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Queen's Medical Research Institute, University of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <state>Midlothian</state>
        <zip>EH16 4TJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicholas B Spath, MBBS BSc</last_name>
      <phone>0131 242 6515</phone>
      <email>nick.spath@ed.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>July 20, 2018</study_first_submitted>
  <study_first_submitted_qc>July 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2018</study_first_posted>
  <last_update_submitted>July 30, 2018</last_update_submitted>
  <last_update_submitted_qc>July 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Hypertrophic</mesh_term>
    <mesh_term>Cardiomyopathy, Dilated</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

